Russian Court provides first compulsory license for production of a US drug

15 June 2018

A Russian pharmaceutical company for the first time has received a license for the production an analogue of a drug in Russia, the rights for which are owned by a global drugmaker, reports The Pharma Letter local correspondent,

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...

Biotechnology

Increased sales of multiple myeloma drug Revlimid boost Celgene's profits

28 July 2016

Pharmaceutical

Bayer starts legal proceedings in Russia due to violation of IP rights

7 February 2018

Pharmaceutical

Takeda to produce innovative MM drug in Russia

2 August 2018

Generics

Russia’s Axelpharm demands compulsory license on Pfizer’s cancer drug Bosulif

6 February 2024

More ones to watch >

Company Spotlight

Neurizon Therapeutics

A clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and broader neurodegenerative biology. Neurizon aims to advance its lead small-molecule candidate into pivotal clinical testing and position it for regulatory evaluation and eventual patient access.